Keyphrases
Chronic Lymphocytic Leukemia
100%
Mantle Cell Lymphoma
75%
Ibrutinib
56%
TP53 mutation
50%
Tumor Protein p53 (TP53)
40%
Relapsed or Refractory
35%
Rituximab
35%
European Research
33%
Minimal Residual Disease
32%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
30%
5-year Follow-up
25%
CD52
25%
Diagnostic Criteria
25%
Cell Analysis
25%
Mutation Analysis
25%
Disease Activity
25%
Lenalidomide
25%
Molecular Surveillance
25%
Bruton's Tyrosine Kinase
25%
Phase II Trial
25%
Lymphoma Patients
25%
Flow Cytometry
25%
Rituximab Therapy
25%
Result Interpretation
25%
European Society
25%
Phase II Study
25%
B-cell Receptor Signaling
20%
TP53 Gene
16%
Peripheral Blood
16%
Medicine and Dentistry
Mantle Cell Lymphoma
75%
B-Cell Chronic Lymphocytic Leukemia
75%
Rituximab
55%
Ibrutinib
50%
Diagnosis
32%
Minimal Residual Disease
32%
Flow Cytometry
25%
Bruton Tyrosine Kinase
25%
Lenalidomide
25%
Autologous Stem Cell Transplantation
25%
Arm
25%
Chronic Lymphocytic Leukemia
25%
